CCHT(SZ:000661) Xin Lang Cai Jing·2026-01-08 08:34Core Viewpoint - Changchun High-tech announced that its subsidiary, Jinsai Pharmaceutical, has had its clinical trial application for the domestically produced injectable GenSci136 accepted by the National Medical Products Administration [1] Group 1: Product Development - Injectable GenSci136 is a Class 1 therapeutic biological product independently developed by Jinsai Pharmaceutical, intended for the treatment of Immunoglobulin A Nephropathy (IgAN) [1] - The drug functions as a B-cell maturation antigen (BCMA) trimeric fusion protein, capable of binding to B lymphocyte stimulator (BlyS) and a proliferation-inducing ligand (APRIL) [1] - GenSci136 has the potential to block the interaction between BlyS, APRIL, and B cell membrane receptors, which may help in treating various autoimmune diseases characterized by fluid immune disorders and tissue damage caused by pathogenic antibodies [1]